Physician profile
Daniel R Frese
NPI 1134188006
$486.74
in general payments reported to CMS, 2019-2025
10 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $121 · 2020: $20.59 · 2021: $142 · 2022: $203.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $138.26 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $121.14 | 2021-2022 | |
| Novo Nordisk INC | $54.29 | 2022 | |
| Lilly USA, LLC | $50.72 | 2021-2022 | |
| Sunovion Pharmaceuticals INC. | $32.83 | 2019 | |
| Mylan Specialty L.P. | $30.73 | 2019-2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $20.59 | 2020 | |
| Astellas Pharma US INC | $12.90 | 2019 | |
| Electromed, INC. | $12.79 | 2021 | |
| Siemens Medical Solutions USA, INC. | $12.49 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Frese listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.